Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ High Yield Corporate Bond ETF vs Eli Lilly And Co — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.2 (market cap $17.89B), while Eli Lilly And Co trades at $1,175.62 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 58.1× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days and Eli Lilly And Co for 93 Days on average.
| HYG | LLY | |
|---|---|---|
Market Cap | $17.89B | $1.04T |
Volume | 44,866,592 | 3,064,878 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $1.28K |
52-Week Low | $76.90 | $799.57 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HYG (iShares iBoxx $ High Yield Corporate Bond ETF) trades at $77.115, down 0.08% with a bearish technical signal from moving averages. The fund has shown unusual options activity recently amid a challenging bond market environment where Treasury yields have reached multi-year highs. Recent dividend payments of $0.34-$0.44 per share provide income support, but the overall technical picture remains weak with significant selling pressure.
The outlook for HYG remains challenged by rising interest rates and bond market volatility. While the fund offers attractive yield income through regular dividends, the bearish technical momentum and elevated Treasury yields create headwinds for price appreciation. Key risks include further rate hikes and credit spread widening in the high-yield bond market.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
